Tracking Your Liver Health: Which Numbers Matter Most?

You walk out of your doctor's appointment with lab results in hand. ALT: 78. AST: 65. Platelets: 210. FIB-4: 0.89. Waist circumference: 94 cm. Blood glucose: 115. The numbers are baffling — are they good or bad? What should you be watching? And how often should you get them checked? Understanding which metrics matter, how to interpret them, and when to track them is essential for navigating MASLD recovery. Fortunately, you don't need to memorize all of this — you just need to understand the core story these numbers tell.

The Core Biomarkers: What Each One Reveals

ALT and AST: Liver cell damage

ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes released when liver cells are damaged or dying. In MASLD, ALT is typically higher than AST early on — this difference is actually useful diagnostically. If your AST starts rising toward or above your ALT level, it can signal that fibrosis is developing, which is why tracking both over time matters more than the absolute values.

Normal ALT is typically under 40 IU/L, but many experts now recognize that "normal" laboratory ranges may be too lenient for MASLD. An ALT over 30 in women or 40 in men, even if technically "normal," suggests liver stress and warrants investigation.

GGT: Oxidative stress and inflammation

GGT (gamma-glutamyl transferase) is less specific than ALT and AST but tells an important story: it indicates oxidative stress and inflammation in your liver. Elevated GGT suggests your liver is working harder than it should be, dealing with excess lipids and generating damaging free radicals. Tracking GGT alongside ALT and AST gives you a more complete picture of hepatic inflammation.

Platelets: A harbinger of fibrosis

Platelets are blood clotting cells. Normally, your spleen releases them into circulation at a steady rate. But when your liver develops fibrosis, portal pressure increases, causing the spleen to enlarge and sequester platelets. A platelet count below 150,000/uL (the lower end of "normal") may signal early fibrosis, even if ultrasound or other imaging appears normal. This is why platelet count is part of the FIB-4 calculation and why watching it over time matters.

FIB-4 Index: Non-invasive fibrosis assessment

FIB-4 is a simple calculation using your age, AST, ALT, and platelet count. It's the most validated non-invasive test for identifying advanced fibrosis (stage 3–4). The thresholds are straightforward:

• FIB-4 < 1.3: Low risk of advanced fibrosis; can be managed in primary care
• FIB-4 1.3–2.67: Intermediate risk; further assessment may be needed
• FIB-4 > 2.67: High risk; specialist evaluation is recommended

What's powerful about FIB-4 is its negative predictive value: if your FIB-4 is low, you can be reassured that you don't have advanced fibrosis. This single number, calculated from routine blood work, is remarkably accurate for ruling out the scarring that would require intensive specialist management.

Body Metrics: The Visible Signs of Change

Weight and weight trends

Weight doesn't tell the whole story — you can be metabolically unhealthy at any weight. However, intentional weight loss of 5–10% is associated with improvements in liver steatosis. Tracking weight over 4–8 week intervals (not daily) helps you see whether your interventions are working while avoiding obsessive monitoring.

Waist circumference: A better predictor than BMI

Waist circumference directly reflects visceral fat — the dangerous type that accumulates around your organs and drives liver fat. Research shows waist circumference is a stronger predictor of NAFLD risk than BMI. For meaningful change tracking, measure yourself monthly at the same time of day (early morning, before eating) at the level of your navel. A reduction of 2–4 cm over 8–12 weeks signals meaningful visceral fat loss.

BMI: Context, not destiny

Body Mass Index (weight in kg / height in m squared) is easy to calculate but limited. It conflates muscle mass with fat and doesn't distinguish visceral from subcutaneous fat. That said, it's useful as a tracking metric in conjunction with waist circumference and weight.

Lifestyle Metrics: The Upstream Drivers

Your lab values are a lagging indicator — they change weeks or months after your behaviors shift. To get ahead of the curve, also track:

• Fasting compliance: How consistently you're adhering to your fasting protocol (if your treatment includes intermittent fasting or caloric restriction).
• Sleep duration and quality: 7–9 hours per night. Sleep directly impacts cortisol, glucose metabolism, and liver inflammation.
• Physical activity: Minutes of moderate or vigorous activity per week. Aim for 150–300 minutes of moderate activity or 75–150 minutes vigorous.
• Resting heart rate: Measured first thing in the morning, before getting out of bed. A declining resting heart rate reflects improving cardiovascular fitness and metabolic health.
• Meal consistency and nutrition: Not calorie-counting obsessively, but noticing whether you're eating primarily whole foods, adequate protein, and limiting ultra-processed items.

These lifestyle metrics often shift first — within 2–4 weeks — whereas lab values may take 8–12 weeks to respond. Tracking them keeps you motivated and provides early evidence that your efforts are working at a cellular level.

How Often Should You Get Lab Work?

Guidelines vary, but a reasonable framework is:

• Baseline assessment: Complete liver panel (ALT, AST, GGT, bilirubin, albumin, INR) plus complete blood count (for platelet count). Calculate FIB-4. Get baseline ultrasound or transient elastography (FibroScan) if available.
• Initial follow-up: 8–12 weeks after starting treatment, to assess early response.
• Ongoing monitoring: Every 3–6 months, depending on baseline fibrosis risk and rate of change. If FIB-4 is stable and low, you may extend intervals to 6–12 months.
• If fibrosis is present: More frequent monitoring (every 3 months) and specialist involvement.

The goal isn't to test obsessively but to establish a pattern and catch unfavorable trends early.

How LivaFast Centralizes Your Data

Logging individual lab values in different places — your patient portal, a notebook, your doctor's fax machine — is tedious and easy to lose track of. LivaFast's Lab Value Tracking feature centralizes all your biomarkers in one place. You log ALT, AST, GGT, platelets, and other values as they come back, and the app displays them as trends over time. Seeing your ALT drop from 95 to 62 to 48 is motivating in a way that isolated data points aren't.

Your Liver Progress Score (LPS) synthesizes these biomarkers (along with body metrics and lifestyle data) into a single composite score that trends upward as your liver health improves. LPS isn't meant to replace your doctor's interpretation — it's meant to give you at-a-glance feedback on whether your overall trajectory is improving.

The FIB-4 Calculator is built directly into LivaFast. As soon as you log your age, AST, ALT, and platelet count, the app calculates your FIB-4 and interprets it in plain language: "Your FIB-4 is 1.1, which indicates low risk of advanced fibrosis. Continue your current management plan and recheck in 3–6 months."

The Doctor Summary PDF export compiles all your tracked values — labs, body metrics, lifestyle data, fasting history, activity level — into a professional summary you can print and bring to your next appointment. This saves your doctor time and ensures they have the complete picture of your recovery.

The 12-Week Journey is structured around testing milestones. The app prompts you to schedule labs at strategic points (baseline, week 8, week 12) so you can measure progress and adjust your approach based on how your body is responding.

Key Takeaways

• Focus on trends, not individual values: ALT, AST, and GGT are more informative when tracked over time. A single "normal" result doesn't indicate recovery; a downward trend does.
• FIB-4 is your fibrosis snapshot: This single calculation from routine labs is a powerful, non-invasive way to assess your risk of advanced scarring. Low FIB-4 is reassuring.
• Waist circumference and weight matter more than BMI alone: These body metrics track visceral fat loss more accurately than overall BMI.
• Lifestyle metrics lead lab values: Sleep, activity, and fasting consistency shift within weeks; lab values follow within 8–12 weeks. Don't wait for labs to know you're on the right track.
• Check labs every 3–6 months: More frequent than yearly, but not so often that normal variation creates alarm. Space them out enough to see meaningful change.

Sources

1. Noninvasive Assessment of Liver Fibrosis in NAFLD — Clinical Gastroenterology and Hepatology
2. Non-alcoholic fatty liver disease — PMC
3. Elevated ALT/AST ratio as a marker for NAFLD risk and severity — Frontiers in Endocrinology
4. Spare Me the Jab: Noninvasive Assessment of Patients with MASLD — AASLD
5. AST/ALT Ratio as a clinical marker — ScienceDirect Topics

---

This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your treatment plan.